

List of Figures

Figure No.	Title	Page
1	Targets of supplement use (percentage of 2009 retail value) (NHS, 2011)	1
2	Market share (in £ million) of supplement in 2009 (NHS, 2011)	2
3	Cartilage breakdown (Novartis osteocerein brochure, n.d.)	6
4	Inflammatory cascade in synovial joint (Novartis osteocerein brochure, n.d.)	7
5	Diacerein as a pro-drug of rhein (Nicolas et al., 1998)	18
6	Molecular pathogenesis of osteoarthritis (NYU med osteoarthritis, n.d.)	24
7	Pre-membrane effect of rhein (Novartis osteocerein brochure, n.d.)	26
8	Post-membrane effect of rhein (Novartis osteocerein brochure, n.d.)	27
9	Anti-catabolic effect of rhein (Novartis osteocerein brochure, n.d.)	28
10	Pro-anabolic effects of diacerein (Novartis osteocerein brochure, n.d.)	30
11	Linearity of six calibration curves (values expressed as mean \pm STD)	55
12	Sample chromatogram of sample plasma	57
13	Chromatogram of subject 6 at time point 0.75 hr	60
14	Chromatogram of subject 1 at time point 0.75 hr	62
15	Comparison of subjects C _{max} prior to glucosamine administration and post glucosamine administration. (n=6)	73
16	Comparison of subjects AUC _{0-t} prior to glucosamine administration and post glucosamine administration. (n=6)	73